Cargando…
Liquid Biopsy Prevents Inaccurate Her2 Status Determination by in situ Hybridization in a Patient with Invasive Ductal Adenocarcinoma of the Breast: Case Report
Utilization of circulating tumor DNA as a novel and noninvasive test for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In the wake of FDA approval of a liquid biopsy test, it is important for clinicians to acknowledge the obvious clinical u...
Autores principales: | Tzeng, Yen-Dun Tony, Chang, Shih-En, Mei, Rui, Javey, Manana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649247/ https://www.ncbi.nlm.nih.gov/pubmed/29071002 http://dx.doi.org/10.1159/000480698 |
Ejemplares similares
-
Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma
por: Buscail, Etienne, et al.
Publicado: (2019) -
Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis
por: Li, Xiaoping, et al.
Publicado: (2016) -
Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma
por: Osei-Bordom, Daniel C., et al.
Publicado: (2022) -
Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests
por: Vyberg, Mogens, et al.
Publicado: (2015) -
Ductal Carcinoma In Situ and Sentinel Lymph Node Biopsy
por: Son, Bok Kyoung, et al.
Publicado: (2011)